Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.52 |
| ▸ | CCR3 | P51677 | 5/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.46 |
| ▸ | ATF4 | P18848 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899687 | 1.00 | HRH1 (0.52) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4899710 | 0.93 | HRH1 (0.49) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4915693 | 0.93 | HRH1 (0.49) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL14046035 | 0.93 | HRH1 (0.46) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4903507 | 0.92 | ATF4 (0.43) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4903321 | 0.92 | ATF4 (0.43) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4897775 | 0.90 | ATF4 (0.42) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4897765 | 0.90 | ATF4 (0.42) | HRH1CCR3ADRB3ADRB2ADRB1 | |
| SCHEMBL4901845 | 0.88 | ATF4 (0.44) | HRH1CCR3ADRB3ADRB1ATF4 | |
| SCHEMBL4892638 | 0.88 | ATF4 (0.44) | HRH1CCR3ADRB3ADRB1ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008058198-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | CARDIOME PHARMA CORP. (CA) | 2008-05-15 | — | — | WO | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ADRB3, PDE3A, ADRB1 | HRH1 647/4885CCR3 1707/4885ADRB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.